9 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 7 Phase 2, 4 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 3, Completed 2, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 4 | Completed 3, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Emerald Clinical Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes MKP10241, Placebo - Type 2 Diabetes Mellitus (T2DM), Food Effect | Phase 2 | Recruiting | Mankind Pharma Limited | 68 | 2025-08-12 | 2025-09-29 |
| NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers NanaBis™, Oxycodone CR, Placebo Spray - Cancer Related Pain | Phase 3 | Unknown | Medlab Clinical | 360 | 2023-11-01 | 2022-04-12 |
| BAT7104 in Patients With Advanced Solid Tumours BAT7104 - Patients With Advanced Solid Tumors | Phase 1 | Completed | Bio-Thera Solutions | 14 | 2022-04-29 | 2024-10-18 |
| Osteosarcoma Maintenance Therapy With OST31-164 OST31-164 - Bone Cancer | Phase 2 | Active not recruiting | Emerald Clinical Inc. | 39 | 2021-10-21 | 2025-01-22 |
| Dapagliflozin Treatment in Type 2 Diabetes Dapagliflozin 10 MG [Farxiga] - Diabetes Mellitus, Type 2, Impaired Renal Function | Phase 4 | Completed | Emerald Clinical Inc. | 17 | 2021-04-20 | 2025-04-24 |
| Treatment With 5-AminoLEvuliNic Acid Before Cardiac Surgery 5-Aminolevulinic Acid hydrochloride (5-ALA), Placebo, Sodium ferrous citrate (SFC) - Cardiac Surgical Procedures, Coronary Artery Bypass | Phase 2 | Completed | University of Oxford | 48 | 2021-02-01 | 2025-06-25 |
| Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease Rivaroxaban 2.5 Mg Oral Tablet, Placebo - Chronic Kidney Diseases, Dialysis-dependent Kidney Failure | Phase 3 | Completed | The George Institute | 1753 | 2021-01-18 | 2026-03-23 |
| A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease AZD5718, Dapagliflozin 10 mg, Placebo - Chronic Kidney Disease | Phase 2 | Terminated | AstraZeneca | 613 | 2020-10-01 | 2024-12-20 |
| Global Kidney Patient Trials Network Kidney Diseases | Completed | The George Institute | 5999 | 2020-05-05 | 2025-12-15 | |
| Dapagliflozin in Respiratory Failure in Patients With COVID-19 Dapagliflozin 10 milligram (mg), Placebo - COVID-19 | Phase 3 | Completed | Saint Luke's Health System | 1250 | 2020-04-22 | 2022-06-10 |
| Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients CYT107, Placebos - Sepsis, Severe | Phase 2 | Terminated | Revimmune | 21 | 2019-06-01 | 2021-10-27 |
| A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | Helsinn Healthcare SA | 404 | 2018-03-16 | 2020-06-01 |
| Protocol for a Multicentre Survey of Patients With Treatment Resistant Hypertension N/A, observational study - Treatment Resistant Hypertension | Completed | Emerald Clinical Inc. | 1500 | 2016-11-01 | 2018-02-19 | |
| Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung pazopanib - Osteosarcoma, Metastatic Osteosarcoma | Phase 2 | Terminated | Emerald Clinical Inc. | 12 | 2013-04-01 | 2021-04-13 |
| Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma pazopanib - Chondrosarcoma, Metastatic Chondrosarcoma | Phase 2 | Completed | Emerald Clinical Inc. | 47 | 2011-04-01 | 2023-03-10 |
Renal Insufficiency, Chronic (3) · Diabetes Mellitus, Type 2 (2) · Diabetic Nephropathies (2) · Osteosarcoma (2) · Aortic Valve Disease (1) · Bone Neoplasms (1) · COVID-19 (1) · Cancer Pain (1) · Cardiovascular Diseases (1) · Chondrosarcoma (1) · Diabetes Mellitus (1) · Glomerulonephritis (1) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranous (1) · Glomerulosclerosis, Focal Segmental (1)
dapagliflozin (3) · pazopanib (2) · AZD5718 (1) · Aminolevulinic Acid (1) · Dexamethasone (1) · Observation (1) · Oxycodone (1) · Rivaroxaban (1) · Saline Solution (1) · ferrous citrate (1) · netupitant, palosentron drug combination (1)
United States (8) · Australia (4) · Canada (3) · United Kingdom (3) · Argentina (2) · Brazil (2) · France (2) · Germany (2) · India (2) · Malaysia (2) · Taiwan (2) · Belgium (1) · Georgia (1) · Hungary (1) · Israel (1)
Arash Yavari, DPhil MRCP (1) · Arthur Staddon, MD (1) · Hiddo J. L. Heerspink (1) · Hiddo JL Heerspink (1) · Hiddo Lambers Heerspink (1) · Martin Gallagher (1) · Mikhail Kosiborod, MD (1) · Richard Hotchkiss, MD (1) · Robert Petit, PhD (1) · Sradha Kotwal (1) · Stephen Hall, MBBS, FRACP (1) · Sunil Badve (1) · Warren A Chow, MD (1) · Warren Chow, MD (1)
PMID 34302745, PMID 34805632, PMID 35075361, PMID 35699910, PMID 36527702, PMID 36906875, PMID 38770818, PMID 39661388, PMID 40739638, PMID 42240165